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TRIF/TICAM-1 (TIR domain-containing adaptor inducing
interferon-/TIR domain-containing adaptor molecule 1) is
the adaptor protein in the Toll-like receptor (TLR) 3 and
4 signalling pathway that leads to the production of type 1
interferons and cytokines. The signalling involves TIR (Toll/
interleukin-1 receptor) domain-dependent TRIF oligomeriza-
tion. A protease-resistant N-terminal region is believed to be
involved in self-regulation of TRIF by interacting with its TIR
domain. Here, the structural and functional characterization
of the N-terminal domain of TRIF (TRIF-NTD) comprising
residues 1–153 is reported. The 2.22 A˚ resolution crystal
structure was solved by single-wavelength anomalous diffrac-
tion (SAD) using selenomethionine-labelled crystals of TRIF-
NTD containing two additional introduced Met residues
(TRIF-NTDA66M/L113M). The structure consists of eight anti-
parallel helices that can be divided into two subdomains, and
the overall fold shares similarity to the interferon-induced
protein with tetratricopeptide repeats (IFIT) family of
proteins, which are involved in both the recognition of viral
RNA and modulation of innate immune signalling. Analysis
of TRIF-NTD surface features and the mapping of sequence
conservation onto the structure suggest several possible
binding sites involved in either TRIF auto-regulation or
interaction with other signalling molecules or ligands. TRIF-
NTD suppresses TRIF-mediated activation of the interferon-
promoter, as well as NF-B-dependent reporter-gene activity.
These findings thus identify opportunities for the selective
targeting of TLR3- and TLR4-mediated inflammation.
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1. Introduction
The innate immune system constitutes the first line of defence
against microbial infection or endogenous danger signals.
Pathogen-associated or danger-associated molecular patterns
(PAMPs/DAMPs) are recognized by pattern-recognition
receptors (PRRs) such as the membrane-bound Toll-like and
C-type lectin receptors (TLRs and CLRs) or the cytosolic
NOD-like and RIG-I-like receptors (NLRs and RLRs)
(Bonardi et al., 2012; Eisena¨cher & Krug, 2012; Kawai &
Akira, 2010; Kingeter & Lin, 2012). After PAMP/DAMP
recognition, these receptors recruit specific adaptor proteins
that determine the specificity of inflammatory response via the
activation of distinct transcription factors and pro-inflamma-
tory genes (Werts et al., 2006; Ve et al., 2012).
TLRs are the best-characterized members of the PRR
family and recognize PAMPs such as lipopolysaccharides,
lipopeptides or bacterial flagellin at the surface of immune
cells, while viral or microbial nucleic acids are recognized
by endosomally localized TLRs (Barton & Kagan, 2009).
TLRs contain a PAMP-recognizing leucine-rich repeat (LRR)
domain, a transmembrane helix and a cytosolic TIR (Toll/
interleukin-1 receptor) domain involved in TIR–TIR domain
interactions. PAMP binding leads to oligomerization of TLRs
and consequently their TIR domains, which facilitates the
recruitment of cytosolic TIR domain-containing adaptor
proteins and signalling. The selective recruitment of one or
several adaptors to specific TLRs triggers the activation of
distinct signalling pathways (O’Neill & Bowie, 2007; Akira
et al., 2006; Ve et al., 2012). TRIF/TICAM-1 (TIR domain-
containing adaptor inducing interferon-/TIR domain-
containing adaptor molecule 1) is directly recruited to TLR3,
while association with TLR4 requires the TIR domain-
containing bridging adaptor TRAM/TICAM-2 (TRIF-related
adaptor molecule/TIR domain-containing adaptor molecule
2). TRIF orchestrates a signalling response characterized
by the inducible expression of interferon- (IFN) and IFN-
dependent genes via the activation of the transcriptional
factors IRF-3, NF-B and AP-1 (Oshiumi, Matsumoto et al.,
2003; Yamamoto et al., 2003; Fitzgerald et al., 2003; Oshiumi,
Sasai et al., 2003).
In the cytoplasm of resting cells, TRIF is expressed at a
low level in a diffuse form (Oshiumi, Matsumoto et al., 2003;
Funami et al., 2007), while in poly(I:C)-stimulated cells TRIF
first transiently associates with TLR3 and subsequently (after
dissociation from the receptor) forms speckle-like structures
that also contain downstream signalling molecules (Funami
et al., 2007; Tatematsu et al., 2010). Human TRIF (712 amino
acids) consists of an N-terminal protease-resistant domain
with a predicted helical structure followed by a proline-rich
unstructured region containing TBK1 (TANK-binding kinase)
and TRAF6 (tumour necrosis factor receptor-associated
factor 6) binding motifs, a central TIR domain and a
C-terminal region containing an RIP homotypic interaction
motif (RHIM) (Fig. 1). Both the TIR and the RHIM domains
are required for TRIF homo-oligomerization (Funami et al.,
2008). The TIR domain also facilitates the direct interaction
with TLR3 and TRAM through TIR–TIR domain inter-
actions, while heterotypic RHIM–RHIM domain interactions
enable TRIF to associate with the death domain-containing
kinases RIP1 and RIP3, leading to NF-B activation and cell
death (Meylan et al., 2004; Han et al., 2004; Kaiser & Offer-
mann, 2005; He et al., 2011). Recruitment of TRAF6 also
results in NF-B activation (Sasai et al.,
2010), while binding of TBK1 leads to
IRF-3 activation and IFN induction
(Tatematsu et al., 2010; Han et al., 2010).
Several regulatory molecules [for
example, members of the tripartite
motif (TRIM) family of proteins]
further regulate the signalling either
positively or negatively to maintain a
balanced response, as both over-
activation and underactivation of TRIF-
mediated signalling have undesirable
effects. The molecular mechanisms of the interaction of TRIF
with its binding partners are unknown.
A deletion mutant of TRIF lacking the N-terminal
protease-resistant domain (residues 1–176) has a higher ability
for IFN promoter activation compared with wild-type TRIF
and forms speckle-like structures in resting cells (Tatematsu
et al., 2010). Immunoprecipitation and protein-fragment
complementation analyses have shown that the TRIF
N-terminal domain interacts with the TIR domain, which
suggests that it can fold back onto the TIR domain in the
resting state of TRIF, and acts as a negative regulator
preventing downstream signalling molecules such as TBK1,
RIP1/3 and TRAF6 from accessing their binding sites.
To understand the molecular basis of TRIF auto-regulation,
we solved the crystal structure of the N-terminal domain
of TRIF (TRIF-NTD) at 2.22 A˚ resolution. The structure
contains eight antiparallel -helices that can be divided into
two subdomains by a long linker region. The overall fold of
TRIF-NTD shares significant structural similarity to the IFN-
induced protein with tetratricopeptide repeats (IFIT) family
of proteins, which have been shown to bind viral RNA and to
regulate innate immune responses by modulating interactions
between components in the type 1 IFN signalling pathway.
Analysis of the structure reveals specific surface regions that
could be involved in TRIF auto-regulation or interact with
other signalling molecules or ligands. Reporter assays in
transfected cells show that TRIF-NTD suppresses TRIF-
mediated induction of both the IFN promoter and an
NF-B-dependent promoter, and could therefore serve as
an experimental tool and therapeutic reagent for targeting
TLR3- and TLR4-mediated inflammation.
2. Materials and methods
2.1. Structure determination and refinement
Details of the expression, purification and X-ray diffraction
data collection of TRIF-NTD have been reported previously
(Ullah et al., 2013). In brief, we crystallized the N-terminal
protein fragment of TRIF encoding residues 1–153 (TRIF-
NTD). The structure was solved by single-wavelength anom-
alous diffraction (SAD) using selenomethionine-labelled
crystals of TRIF-NTD containing two additional Met residues
(TRIF-NTDA66M/L113M). X-ray diffraction data sets were
collected at two wavelengths [1.1070 A˚ (high-resolution data
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Figure 1
Schematic representation of the primary structure of TRIF, highlighting structural and functional
motifs. TRIF-NTD (TRIF N-terminal domain) is a globular domain consisting of eight helices
(this work). TBK1-BM (TANK-binding kinase 1 binding motif) corresponds to residues 191–200
(Tatematsu et al., 2010). TRAF6-BM (TRAF6-binding motif) and TRAF2-BM (TRAF2-binding
motif) correspond to residues 230–235 and 333–338, respectively (Sasai et al., 2010). Residues
390–538 are predicted to correspond to a TIR domain. An RHIM (receptor-interacting protein
homotypic interaction motif) is found in the C-terminal region of TRIF (Meylan et al., 2004).
set) and 0.9793 A˚ (Se peak data set)] and the resolution limits
of the data sets corresponded to 2.22 and 2.48 A˚, respectively.
The data for the high-resolution data set could not be used to a
resolution higher than 2.22 A˚ because of a rapid drop in data
completeness owing to the geometry of data collection. The
crystals had the symmetry of space group P1 with four
molecules in the asymmetric unit. SAD phasing was
performed using the Se peak data set and the program
AutoSol in the PHENIX suite (Adams et al., 2013). The initial
model was built into the resulting density using ARP/wARP
(Langer et al., 2008) and several cycles of refinement were
performed using phenix.refine in the PHENIX suite with
model building using Coot (Emsley et al., 2010) using the high-
resolution data set. Programs from the CCP4 suite (Winn et
al., 2011) were also used at different stages of structure
determination. Crystals of wild-type TRIF-NTD diffracted
X-rays to resolutions between 1.9 and 2.8 A˚. The data from
these crystals were originally processed in space group
P212121, with unit-cell parameters a = 48.02, b = 77.18,
c = 85.15 A˚ (Ullah et al., 2013), and although a molecular-
replacement solution could be found using Phaser (McCoy
et al., 2007) with the TRIF-NTDA66M/L113M structure as a
template, the model could not be refined (Rwork > 44% and
Rfree > 48%). However, the data from one of the TRIF NTD
crystals that diffracted X-rays to 2.8 A˚ resolution could also be
processed in space group P1 with a similar unit cell to TRIF-
NTDA66M/L113M. This structure was solved using molecular
replacement and refined using BUSTER-TNT (Blanc et al.,
2004) to final Rwork and Rfree values of 25.2 and 29.1%,
respectively. Comparison of the packing of the molecules in
the crystals of the P212121 symmetry wild-type TRIF-NTD,
based on the possible molecular-replacement solution, with
those in the crystals of the P1 symmetry TRIF-NTD and
TRIF-NTD A66M/L113M revealed a related but not identical
arrangement of molecules. We suggest that the packing of
molecules in the crystals deviates slightly from an arrange-
ment that would be compatible with higher (space group
P212121) crystallographic symmetry (i.e. such that the
symmetry axes relating the molecules could be propagated
in the crystal as crystallographic symmetry). PyMOL (http://
www.pymol.org) and Pro-origami (Stivala et al., 2011) were
used to generate the figures. Coordinates and structure factors
for TRIF-NTDA66M/L113M and wild-type TRIF-NTD have
been deposited in the Protein Data Bank as entries 4bsx and
4c0m, respectively.
2.2. Analysis of the structure
The structure was compared with available structures using
DALI (Holm & Rosenstro¨m, 2010). The electrostatic poten-
tial was mapped onto the surface using APBS (Unni et al.,
2011). Multiple sequence alignments were performed using
ClustalW (Larkin et al., 2007) and formatted using ESPript
(Gouet et al., 2003). Interfaces were analyzed using the PISA
server (Krissinel & Henrick, 2007); the buried surface areas
reported correspond to the total buried surface area contrib-
uted by both interacting partners.
2.3. Transient transfection of cells and reporter activity
Human embryonic kidney (HEK) 293 cells were incubated
in Dulbecco’s modified Eagle’s medium supplemented with
10% foetal calf serum, 2 ml glutamine and maintained in a
310 K humidified atmosphere. The cells (2  104 ml1) were
seeded in 96-well plates 24 h prior to transfection. Transfec-
tions were performed with Fugene 6 (Roche Diagnostics).
NF-B-dependent reporter-gene expression was determined
using the 5 B-luciferase reporter construct (Stratagene)
concomitantly with the indicated vectors. The p125-luc
luciferase plasmid contains the full-length IFN promoter
upstream of the firefly luciferase gene and is referred to as
the IFN-luciferase reporter. The Renilla luciferase-thymidine
kinase-encoding plasmid (pRL-TK; Promega, Madison,
Wisconsin, USA) was used to normalize for transfection effi-
ciency and pEF-BOS empty vector was used to maintain
constant amounts of DNA. Cells transfected with pEF-Bos-
TRAM, pEF-Bos-TRIF and Flag-tagged TLR3 either in the
presence or absence of TRIF-NTD (in a pEF6/V5-His-TOPO
vector) were lysed using Passive Lysis Buffer (Promega) and
assayed for luciferase and Renilla luciferase activity using
the Renilla Luciferase Assay System reagent (Promega).
Luminescence readings were corrected for Renilla luciferase
activity and expressed as fold increases over nonstimulated
control values.
2.4. Biophysical analyses
MALLS (multi-angle laser light scattering) experiments
were carried out using a DAWN HELEOS II 18-angle light-
scattering detector coupled with an Optilab rEX refractive-
index detector (Wyatt Technology) and combined inline with
a Superdex 200 10/300 GL (GE Healthcare) size-exclusion
column connected to a Prominence UFLC (Shimadzu). The
buffer for all experiments corresponded to 10 mM HEPES
pH 7.5, 150 mM NaCl, 2 mM DTT. For circular-dichroism
(CD) analyses, the protein samples were prepared by dialysis
overnight into 10 mM phosphate buffer pH 7.5, 100 mM NaCl.
The concentrations of the proteins were in the range 4–5 mM.
The CD spectra were collected using a Jasco J710 spectro-
polarimeter at 298 K. The measurements were recorded at
0.2 nm wavelength increments from 260 to 195 nm at
20 nm min1 using a 0.1 cm path-length cell, a 1 nm band-
width, a 1 s response time and five accumulations. After
correction for the buffer baseline contribution, the spectra
were analyzed using the online programs CAPITO (Wiede-
mann et al., 2013) and SOMCD (Unneberg et al., 2001).
3. Results and discussion
3.1. Functional characterization of TRIF-NTD
TRIF-NTD has previously been proposed to form an
intramolecular interaction with the TIR domain of TRIF, thus
preventing the homodimerization of TRIF and binding to
downstream signalling molecules (Tatematsu et al., 2010). We
therefore tested whether TRIF-NTD could act functionally as
a dominant negative to inhibit TRIF-induced signalling using
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the TRIF-NTD construct structurally
characterized in this study (TRIF-NTD,
comprising residues 1–153). Expression
of TRIF-NTD did not activate either
the IFN or the NF-B promoter
(Supplementary Fig. S1a1). We first
established a dose of TRIF that
activated both the NF-B and IFN-
luciferase promoters and chose 1 ng of
TRIF DNA as a suboptimal activating
dose, such that we would observe any
inhibition of signalling (Supplementary
Fig. S1b). Ectopic expression of TRIF-
NTD in a 25-fold to 100-fold excess
compared with TRIF was able to inhibit
both TRIF-mediated IFN promoter
activation (Fig. 2a, left panel) and
TRIF-induced NF-B promoter activity
(Fig. 2a, right panel).
To provide further support for the
observed effects of TRIF-NTD on
TRIF-mediated signalling, we demon-
strated that TRIF-NTD is able to
inhibit TRAM-induced IFN or NF-B
promoter activation (left and right
panels in Fig. 2b, respectively). We also
assessed the ability of TRIF-NTD to
suppress TLR3-mediated activation of
signalling pathways. As can be observed
in Fig. 2(c), TRIF-NTD noticeably and
consistently inhibited the degree of
TLR3-induced IFN (left panel) and
NF-B (right panel) promoter activa-
tion, particularly at higher doses.
Importantly, we were successful in
suppressing TRAM-induced activation
of the signalling pathway by TRIF-
NTD. As TRAM is an upstream
activator of TRIF, the ability of
TRIF-NTD to suppress signalling
implies that excess TRIF-NTD is able to
compete with subsequent activation
of TRIF to suppress downstream
signalling. This therefore suggests that
the association between TRIF-NTD
and the TIR domain of TRIF is
dynamic and could be suppressed
through molecular competition if excess
TRIF-NTD is available during
activation.
Taken together, our results support
the theory of Matsumoto and coworkers (Tatematsu et al.,
2010) that excess expression of TRIF-NTD acts to suppress
the activity of TRIF and modulates the downstream signalling
pathways leading to activation of both the IFN or NF-B
promoters. These results suggest that therapeutically targeting
TRIF-mediated signalling with excess TRIF-NTD could
potentially modulate TLR3- or TLR4-mediated signal trans-
duction and inflammation.
research papers
Acta Cryst. (2013). D69, 2420–2430 Ullah et al.  TRIF/TICAM-1 2423
Figure 2
TRIF-NTD inhibits TLR3- and TRIF-mediated activation of the IFN promoter and an NF-B-
dependent promoter. (a) HEK293 cells (2  104 ml1) were transiently transfected for 24 h with
Renilla luciferase-thymidine kinase and IFN-luciferase (left panel) or NF-B-luciferase (right
panel) in conjunction with TRIF (1 ng) and a dose range of TRIF-NTD (25–100 ng). (b) TRAM
(25 ng) activity was inhibited in a dose-dependent manner by the addition of TRIF-NTD (25–
100 ng) and IFN-luciferase (left panel) or NF-B-luciferase (right panel) evaluated following cell
lysis. (c) Cells were made responsive to the TLR3 ligand poly(I:C) (10 mg ml1) by transfection with
TLR3 (5 ng) and were inhibited by co-expression with TRIF-NTD in a dose-dependent manner
(25–150 ng). Results correspond to the mean  standard error and are representative of three
independent experiments.
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: CB5041). Services for accessing this material are described at the
back of the journal.
3.2. Structure determination of
TRIF-NTD
To aid in understanding its function
and in any therapeutic application, we
set out to structurally characterize
TRIF-NTD. Constructs encompassing
residues 1–153 and 1–177 of human
TRIF were produced in Escherichia coli
and purified using a combination of
IMAC (immobilized metal-ion affinity
chromatography) and gel filtration.
Both constructs crystallized, but only
the shorter construct produced diffrac-
tion-quality crystals (Ullah et al., 2013).
The N-terminal region of TRIF does not
share sequence similarity to any
proteins of known structure and only
contains two methionine residues. To
increase the chances of successful
structure determination using SeMet-
based experimental phasing, Ala66 and
Leu113 were mutagenized to methio-
nine residues (TRIF-NTDA66M/L113M).
These positions correspond to methio-
nine residues in several mammalian
TRIF orthologues (Ullah et al., 2013).
The remaining parts of the sequences
are highly conserved, suggesting that
these mutations should not affect the
overall fold of the protein. TRIF-NTD,
TRIF-NTDA66M/L113M and TRIF (resi-
dues 1–177) are all monomeric in
solution (based on MALLS analysis;
Supplementary Fig. S2) and have indis-
tinguishable circular-dichroism spectra
(Supplementary Fig. S3). SeMet-
labelled TRIF-NTDA66M/L113M was
successfully purified and yielded plate-
like crystals which diffracted X-rays to
2.22 A˚ resolution. The crystals had the
symmetry of the triclinic space group
P1. An interpretable electron-density
map was obtained from an SeMet-
labelled derivative using the single-
wavelength anomalous diffraction
(SAD) technique. The structure was
refined to final Rwork and Rfree values of
19 and 24%, respectively, with good
stereochemistry (Table 1). The final
model contains four nearly identical
molecules in the asymmetric unit [the
maximum root-mean-square distance
(r.m.s.d.) for any pair of the molecules
was 0.189 A˚ for all atoms]. The model
contains residues 4–148; no electron density was observed for
residues 1–3 and 149–153, suggesting that these regions have a
disordered or flexible conformation in the crystal.
For wild-type TRIF-NTD we have only been able to obtain
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Table 1
Structure-solution and refinement statistics.
TRIF-NTDA66M/L113M
High-resolution
data set Se peak data set TRIF-NTD
Data-collection statistics
Wavelength (A˚) 1.1070 0.9793 0.9536
Temperature (K) 100 100 100
Detector ADSC Quantum
315r CCD
ADSC Quantum
315r CCD
ADSC Quantum
315r CCD
Crystal-to-detector distance (mm) 300.00 399.99 350.00
Rotation range per image () 1.0 1.0 1.0
Total rotation range () 360 1440 180
Exposure time per image (s) 4.0 1.0 1.0
Space group P1 P1 P1
Unit-cell parameters
a (A˚) 47.31 47.32 48.0
b (A˚) 49.33 49.48 49.4
c (A˚) 70.14 70.32 70.9
 () 88.66 88.55 88.6
 () 77.61 77.63 77.2
 () 72.21 72.26 72.1
Mosaicity () 0.22 0.20 1.2
Resolution range (A˚) 68.40–2.22
(2.35–2.22)
68.62–2.48
(2.63–2.48)
44.51–2.80
(2.95–2.80)
Total No. of reflections 103753 225375 23984
No. of unique reflections 27104 19519 13337
Completeness (%) 93.7 (71.6) 94.8 (68.9) 89.6 (90.4)
Anomalous completeness (%) 88.1 (63.9) 93.2 (60.0)
Multiplicity 3.8 11.6 1.8
Anomalous multiplicity 2.0 5.8
hI/(I)i 10.6 (3.7) 17.1 (4.5) 3.9 (2.0)
Rmeas† (%) 12.0 (43.2) 14.7 (61.4) 20.4 (39.5)
Rp.i.m.‡ (%) 6.1 (22.7) 4.3 (18.8) 14.4 (27.9)
Overall B factor from Wilson plot (A˚2) 23.5 21.4 9.0
Phasing statistics (AutoSolve)
No. of sites (found/all) 11/16
Figure of merit§ 0.38
Overall score (BAYES-CC}  100) 42.32  9.78
R factor (after density modification) 0.26
SKEW†† 0.11
CORRRMS‡‡ 0.75
Refinement statistics
Resolution range (A˚) 47.10–2.22 39.70–2.80
No. of reflections, work set 23845 13335
No. of reflections, test set 1877 680
Rwork§§ (%) 19.01 25.2
Rfree}} (%) 23.90 29.1
No. of non-H atoms
Total 4775 4352
Non-solvent 4487 4352
Water 288 0
Average isotropic B value (A˚2) 22.6 22.7
R.m.s.d. from ideal geometry
Bond lengths (A˚) 0.014 0.010
Bond angles () 1.354 0.970
Ramachadran plot, residues in (%)
Favoured regions 98.94 96.76
Additionally allowed regions 0.88 3.34
Outlier regions 0.18 0.00
† Rmeas =
P
hklfNðhklÞ=½NðhklÞ  1g1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the ith measurement of
the intensity of reflection khl, hI(hkl)i is the mean intensity of reflection hkl and N(hkl) is the number of observations of
intensity I(hkl) (the multiplicity). ‡ Rp.i.m. =
P
hklf1=½NðhklÞ  1g1=2
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ. § An
estimate of phase quality and an indicator of the internal consistency of a solution, ranging from 0 to 1. } The
Bayesian correlation coefficient score. Bayesian estimates of the quality of experimental electron-density maps are
obtained using data from a set of previously solved data sets. †† Skew of the electron density in the map. ‡‡ The
correlation of local r.m.s density. §§ Rwork =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where Fobs and Fcalc are the observed
and calculated structure factors, respectively. }} Rfree is equivalent to Rwork but was calculated using a randomly
selected 7.3% of the reflections, which were excluded from all stages of refinement.
diffraction data to 2.8 A˚ resolution (Table 1). Importantly,
there are no significant differences between the structures of
wild-type TRIF-NTD and TRIF-NTDA66M/L113M (r.m.s.d. of
0.32 A˚ for all four chains in the asym-
metric unit; Supplementary Fig. S4); we
will therefore use the higher resolution
structure of TRIF-NTDA66M/L113M for
all structural analyses in this paper
unless stated otherwise. Representative
electron-density maps are shown in
Supplementary Fig. S5.
3.3. Overall structure of TRIF-NTD
The crystal structure of TRIF-NTD
consists of eight -helices (1–8)
connected by loop regions (Figs. 3a, 3b
and 3c). The structure can be divided into
three parts: the N-terminal 79 residues
form an antiparallel five-helix structure
and residues 92–148 form an antiparallel
three-helix bundle, while residues
80–91 form a long linker loop connecting
the two subdomains. Although the linker
region separates the two subdomains,
they form extensive interactions with
each other, as indicated by the buried
surface area of about 1520 A˚2. These
interactions involve both hydrophobic
and polar residues, contributed predomi-
nantly by helices 1–3 in the first sub-
domain and helices 7–8 in the second
subdomain. Several of these residues are
conserved in TRIF variants from
mammals, fish and birds (Fig. 4). One
distinct interface was observed between
two molecules in the TRIF-NTD crystals,
yielding a dimeric structure with overall
dimensions of 72  44  38 A˚ and a
buried surface area of approximately
1700 A˚2 (Supplementary Fig. S6).
However, analysis of the interface using
PISA (Krissinel & Henrick, 2007)
revealed very few specific side-chain
interactions, suggesting that the interface
is likely to correspond to a nonspecific
crystal-packing interface, which is consis-
tent with MALLS (multi-angle laser light
scattering) data showing that TRIF-NTD
exists as a monomer in solution (Supple-
mentary Fig. S1; Ullah et al., 2013).
Examination of the electrostatic surface
potential of TRIF-NTD revealed that the
charge is distributed unevenly, with the
surface areas contributed by the 3–5
and 7–8 helices and the long loop
connecting the 5 and 6 helices having
an overall electronegative charge, while the face of the
molecule contributed by the 2 helix and the tip of the 6
helix is positively charged (Fig. 5).
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Figure 3
Crystal structure of TRIF-NTD. (a) Secondary structure, TPR-like motif features and subdomain
organization of TRIF-NTD. (b) Cylinder representation of the TRIF-NTD structure. The helices
are labelled 1–8. Subdomains 1 and 2 are highlighted in orange and teal, respectively, while the
loop connecting the subdomains is displayed in green. (c) Cartoon representation of TRIF-NTD
created by the program Pro-origami (Stivala et al., 2011). (d) Structural alignment of TRIF-NTD
TPR-like motifs with typical TPR motifs (TPR1 in phosphatase 5; PDB entry 1a17; Das et al.,
1998). The consensus TPR motifs are displayed above the alignments. (e) Superimposition of
helices 3–5 (orange) with helices 6–8 (teal).
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Figure 4
Multiple sequence alignment of TRIF orthologues. Amino-acid sequences were aligned using ClustalW (Larkin et al., 2007). The positions of the
elements of secondary structure in TRIF-NTD are shown at the top. The alignment was formatted using ESPript (Gouet et al., 2003). Strictly conserved
residues are indicated in white letters on a red background, while similar residues are indicated in red letters in a blue frame. (a) Alignment of the
N-terminal regions of mammalian TRIF orthologues. (b) Alignment of the N-terminal regions of human, chicken and zebra-fish TRIF proteins.
3.4. TRIF-NTD shares structural
similarity with IFIT proteins
A search for structurally similar
proteins using DALI (Holm &
Rosenstro¨m, 2010) identified
significant similarities to tetra-
tricopeptide repeat (TPR)
containing proteins, including
IFN-induced proteins with tetra-
tricopeptide repeats (IFIT) 1
(DALI Z score = 4.4) and 5 (Z =
3.7), the mitochondrial fission
protein 1 (Fis1; Z = 3.5), and
microtubule interacting and
transport (MIT) domain-
containing proteins such as the
VPS4 ATPase (Z = 3.0) and
katanin p60 (Z = 2.6) (Supple-
mentary Fig. S7). TPR is a struc-
tural motif that is present in a
wide range of proteins and is
involved in mediating protein–
protein interactions and multi-
protein complex assembly
(D’Andrea & Regan, 2003). The
MIT domain is also involved in
protein–protein interactions, and
the orientation and the inter-
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Figure 5
Surface properties of TRIF-NTD. (a)
Cylinder representations of TRIF-NTD.
(b) Conserved TRIF-NTD surface
features in human, chicken and zebra-
fish TRIF proteins. The surface is
coloured according to the alignment in
Fig. 4(b); strictly conserved residues are
shown in red and similar residues are
shown in light red, while nonconserved
residues are coloured grey. The posi-
tions of the two largest clefts in
TRIF-NTD (calculated with ProFunc;
Laskowski et al., 2005) are indicated
with black dotted lines. (c) Conserved
surface features between mammalian
TRIF-NTD orthologues. The molecules
are coloured as in (b). (d) Surface
representations of the molecules in (b)
and (c) with the electrostatic potential
(calculated using APBS; Baker et al.,
2001) mapped onto the surface.
Colouring is continuous from blue
(potential +5kT/e) through white to
red (potential 5kT/e). (e) The surface
is coloured according to the hydropho-
bicity of the side chain, with yellow
representing hydrophobic residues and
blue representing residues with polar
side chains. In (a) to (e) the molecules in
the central and right panels have been
rotated relative to the molecule in the
left panel.
helical interactions between the two first helices share a
similarity to TPR motifs (Scott et al., 2005). The TPR motif is
34 amino acids in length and contains two antiparallel
helices (helix A and helix B) with eight loosely conserved
positions, Trp4, Leu7, Gly8, Tyr11, Ala20, Phe24, Ala27 and
Pro32, which mediate the interaction between the two helices
(Blatch & La¨ssle, 1999). In TRIF-NTD, the helix pairs 3–4
and 6–7 resemble TPR motifs, with amino acids typical for
TPRs found at positions 8, 11, 20, 24 and 27 in the first motif,
and 8, 11, 24 and 27 in the second motif (Fig. 3d). Not
surprisingly, these two helix pairs and their succeeding helices
(5 and 8) are structurally similar to each other, with an
r.m.s.d. of 1.4 A˚ for 42 equivalent C atoms (Fig. 3e). However,
the two motifs do not form a continuous repetitive structure in
TRIF-NTD.
The TPR-containing IFIT proteins have the highest level of
similarity to TRIF-NTD, with overall r.m.s.d. values of 3.2 and
3.4 A˚ (for 116 and 120 equivalent C atoms) for IFIT1 and
IFIT5, respectively (Fig. 6, Supplementary Fig. S8). Structu-
rally, IFIT proteins can be divided into three TPR-containing
regions (Yang et al., 2012; Abbas et al., 2013); in IFIT1 and
IFIT5 helices 1–6 form the N-terminal subdomain and helices
7–14 form the central subdomain, while the remaining helices
form the C-terminal subdomain (Fig. 6a). The first subdomain
in TRIF-NTD aligns well with the first five helices of the
N-terminal subdomain of IFIT1, IFIT2 and IFIT5 (r.m.s.d. of
2.32 A˚ for 65 equivalent C atoms for IFIT1), while the second
subdomain in TRIF-NTD aligns well with the three first
helices of the central subdomain in IFIT1, IFIT2 and IFIT5
(r.m.s.d. of 2.5 A˚ for 43 equivalent C atoms for IFIT1; Figs. 6b
and 6c, Supplementary Fig. S8). The relative positions of the
N-terminal and central subdomains in IFIT proteins are also
conserved in TRIF-NTD (Fig. 6c). In both the TRIF-NTD and
the IFIT proteins the first helix of the second subdomain packs
against the concave surface of the N-terminal domain, which
is reminiscent of the interaction between the TPR-containing
protein Fis1 and its ligand (Zhang & Chan, 2007). Interest-
ingly, in the crystal structure of IFIT2 (Yang et al., 2012) the
N-terminal subdomain and the three first helices of the central
subdomain from two different molecules associate to form a
domain-swapped dimer and may explain how IFIT proteins
form homo and hetero complexes. However, it is unlikely that
TRIF-NTD would form similar domain-swapped dimers as
this region of TRIF is not required for homo-oligomerization
(Tatematsu et al., 2010).
IFIT proteins are encoded by a family of genes that are
highly induced after stimulation by IFNs, viral infection and
PAMP recognition and can inhibit viral infection by suppres-
sion of translation initiation and by sequestering of viral
proteins or RNA in the cytoplasm (Diamond & Farzan, 2013).
IFIT proteins modulate interactions between signalling
proteins in the type 1 IFN pathway. IFIT1 has been shown to
disrupt the physical interaction between STING (stimulator
of IFN genes protein) and TBK1 or MAVS (mitochondrial
antiviral-signalling protein) (Li et al., 2009), while IFIT3 can
bridge the interaction between MAVS and TBK1, leading to
an elevated antiviral response (Liu et al., 2011). The latter
interaction requires the N-terminal region of IFIT3, which is
structurally similar to TRIF-NTD, and two glutamate residues
at the end of the 9 helix of IFIT3 have been shown to be
critical for the interaction with TBK1. Although TRIF-NTD
is not required for TRIF–TBK1 interaction, the end of the
equivalent 7 helix contains residues with similar properties,
including two aspartates (Fig. 4a), and the surface region also
has an electronegative charge. Overall, the similarity between
the structures of TRIF-NTD and of the N-terminal region of
IFIT proteins may suggest that they have functionally similar
roles, which is consistent with the previously proposed regu-
latory role for TRIF-NTD in TRIF signalling (Tatematsu et al.,
2010).
3.5. Identification of possible binding sites in TRIF-NTD
involved in TRIF auto-regulation and binding to signalling
partners
One of the suggested functions for TRIF-NTD is binding
to the TRIF TIR domain as part of the auto-regulatory
mechanism (Tatematsu et al., 2010). The amino-acid sequence
of TRIF-NTD is highly conserved in mammals, with sequence
identities ranging from 63 to 100% (Fig. 4a). The equivalent
regions in TRIF variants from bird and fish species only share
34–37% and 24–28% identity with human TRIF, respectively,
but many of the strictly conserved residues are buried and are
critical for stabilizing the structure (Fig. 4b and Supplemen-
tary Fig. S9), suggesting that they have an analogous fold to
human TRIF-NTD. To identify possible binding sites involved
in TRIF auto-regulation, we looked for surface regions
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Figure 6
TRIF-NTD shares structural similarity with IFIT proteins. (a) Crystal
structure of IFIT5 (PDB entry 4hoq; Abbas et al., 2013). The N-terminal,
central and C-terminal regions are shown in pink, yellow and green,
respectively. (b) TRIF-NTD structure in the same orientation as IFIT5 in
(a). Subdomains 1 and 2 are displayed in orange and teal, respectively. (c)
Superposition of IFIT5 and TRIF-NTD. Only helices 1–9 are shown
for IFIT5.
present in the structure that exhibited a high degree of
sequence conservation among TRIF orthologues. Two
programs, ProFunc (Laskowski et al., 2005) and ESPript
(Gouet et al., 2003), were used to consider both sequence and
structural information from mammalian TRIF species and
diverse TRIF sequences from mammals, birds and fish (Fig. 4).
Surface calculations using ProFunc identified two major clefts
with a cutoff volume of >700 A˚3. The two clefts are located
next to each other and may be considered as a continuous
surface feature. The largest cleft has a volume of 1500 A˚3 and
is localized at the junction between the two helical subdomains
(Fig. 5b). This cleft has a length of 30 A˚ and a width of 6–12 A˚,
which could accommodate a six-to-eight-residue polypeptide
chain with extended secondary structure. The side walls of this
cleft consist of residues from the 3, 5, 7 and 8 helices and
the loop connecting the 5 and 6 helices, whereas the base of
the pocket is mostly formed by helix 6, the loop connecting
the 2 and 3 helices and the end of the loop connecting the
5 and 6 helices. This cleft has significant sequence conser-
vation within mammals, but not between mammals, birds and
fish (Figs. 5b and 5c), which may suggest that in these two cases
the cleft has evolved to accommodate different binding part-
ners or that the binding partner differs substantially between
mammals on the one hand and bird and fish species on the
other. The most highly conserved residues within the pocket in
mammalian TRIF are localized deep in the cleft and include
several hydrophobic residues (Leu42, Val69, Val92, Trp94,
Ala95 and Leu99; Fig. 5e). The walls and regions surrounding
the pocket include several conserved polar and charged resi-
dues including Gln40, Asp67, Glu87, Glu88, Asp91, Arg132,
Glu135 and Glu139 (Fig. 5d). Overall, the base of the cleft is
highly hydrophobic, while the entry and exit points have a
negative charge. The second cleft is significantly smaller than
cleft 1 and includes residues from the 2, 6 and 8 helices
and the loop connecting the 2 and 3 helices (Fig. 5b).
Residues Lys29, Leu43, Leu102, Leu103, Glu105 and Glu106,
which are conserved or similar in mammals, birds and fish,
form the floor and walls of one half of cleft 2 (Fig. 5b). These
residues are also part of an extended surface patch on the top
face of the molecule with high similarity in mammalian, bird
and fish TRIF species, suggesting that this region of the TRIF-
NTD molecule might also function as an interaction surface
(Fig. 5b). In addition to the conserved residues in cleft 2, this
surface patch consists of residues Ile14, Ala17, Ala18, Lys22,
Ile59, Ala104, Lys107, Leu108 and Cys109.
4. Conclusions
In this study, we present the structural and functional char-
acterization of the NTD of the TLR signalling adaptor TRIF.
We determined the crystal structure of the protease-resistant
TRIF-NTD (residues 1–153) at 2.22 A˚ resolution by using
SAD phasing with an SeMet-labelled protein containing two
additional introduced Met residues. The structure shows two
helical subdomains connected by a 14-residue linker. The helix
pairs resemble TPR-like motifs and the overall fold of TRIF-
NTD shares significant structural similarity with the IFIT
family of proteins, which are also involved in innate immune
signalling. The structure suggests possible surfaces that could
mediate the interaction with the TIR domain as part of the
proposed auto-regulatory mechanism (Tatematsu et al., 2010)
or possibly with unknown interaction partners. Based on the
similarities to IFIT proteins and to TPR proteins in general,
TRIF-NTD could serve as the sensor domain for an as-yet
unknown ligand, with the interaction exposing the binding
sites for TBK1, resulting in type 1 IFN signalling. This would
also be consistent with the data showing that the deletion of
TRIF-NTD leads to increased IFN production and is also
similar to mechanisms proposed for PRRs such as NLRs and
plant resistance (R) proteins, in which the LRR domain has a
dual sensor and auto-regulatory role. Significantly, exogenous
TRIF-NTD suppressed the activation of both the IFN and
NF-B promoters, providing further evidence for the auto-
regulatory role of NTD in TRIF and suggesting that our
construct could serve as a therapeutic reagent targeting TLR3-
and TLR4-mediated inflammation.
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